The FDA approves Roche (OTCQX:RHHBY) unit Foundation Medicine’s FoundationOne Liquid CDx, a comprehensive pan-tumor liquid biopsy test for solid tumors. The genomic profiling test analyzes more than 300 cancer-related genes and multiple genomic signatures based on circulating cell-free DNA in a blood sample using massively parallel sequencing to detect the four main classes of genomic alterations.
It is also approved as a companion diagnostic for Clovis Oncology’s (NASDAQ:CLVS) PARP inhibitor Rubraca (rucaparib) for certain prostate cancer patients and three first-line tyrosine kinase inhibitors for non-small cell lung cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.